| Title |
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
|
|---|---|
| Published in |
BMC Neurology, October 2013
|
| DOI | 10.1186/1471-2377-13-146 |
| Pubmed ID | |
| Authors |
Deepak MW Balak, Gerald JD Hengstman, Enes Hajdarbegovic, Rob JP van den Brule, Raymond MM Hupperts, Hok Bing Thio |
| Abstract |
Glatiramer acetate (GA) and interferon-beta (IFN-β) are disease-modifying therapies (DMTs) for multiple sclerosis that are administered through subcutaneous (SC) or intramuscular (IM) injections. Skin reactions associated with DMTs are common and may influence patient's health-related quality of life (QoL). We aimed to determine the prevalence of cutaneous adverse events associated with long-term DMT use, and to assess the impact of cutaneous adverse events on QoL. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 1 | 25% |
| Egypt | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 3 | 75% |
| Members of the public | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Portugal | 1 | 2% |
| Unknown | 57 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 15% |
| Other | 7 | 12% |
| Student > Doctoral Student | 5 | 8% |
| Researcher | 5 | 8% |
| Student > Postgraduate | 4 | 7% |
| Other | 8 | 14% |
| Unknown | 21 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 32% |
| Nursing and Health Professions | 4 | 7% |
| Agricultural and Biological Sciences | 4 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Psychology | 3 | 5% |
| Other | 5 | 8% |
| Unknown | 21 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 November 2013.
All research outputs
#13,160,609
of 22,727,570 outputs
Outputs from BMC Neurology
#1,024
of 2,424 outputs
Outputs of similar age
#108,859
of 210,723 outputs
Outputs of similar age from BMC Neurology
#27
of 71 outputs
Altmetric has tracked 22,727,570 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,424 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,723 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.